Eidos Therapeutics Reports Second Quarter 2019 Financial Results
August 01, 2019 16:30 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), today reported its financial results for the second quarter ended June 30, 2019 and provided an...
Eidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare Conference
June 18, 2019 08:00 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, June 18, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will participate in a fireside chat at the 2019 BMO Prescriptions for...
Eidos Therapeutics Reports First Quarter 2019 Financial Results
May 07, 2019 16:30 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, May 07, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the first quarter ended March 31, 2019 and provided an...
Eidos Therapeutics to Present at Two Upcoming Investor Conferences
April 19, 2019 08:00 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, April 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will present at two upcoming investor conferences. Class of 2018...
Eidos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results
April 15, 2019 08:30 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, April 15, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2018...
Eidos Therapeutics Announces Publication in the Journal of the American College of Cardiology (JACC) and Presentation at American College of Cardiology (ACC) Scientific Sessions
March 18, 2019 09:30 ET
|
Eidos Therapeutics, Inc.
AG10 demonstrated equivalent, near-complete stabilization of TTR in wild-type and mutant subjects with TTR amyloid cardiomyopathy (ATTR-CM). AG10 treatment normalized serum TTR levels, a prognostic...
Eidos Therapeutics to Present at 31st Annual ROTH Conference
March 11, 2019 08:00 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, March 11, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management is scheduled to participate in a fireside chat regarding Eidos at the...
Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint
February 27, 2019 07:00 ET
|
Eidos Therapeutics, Inc.
ATTRibute-CM study design, which incorporates feedback from the FDA, has the potential to accelerate registration with a 12-month primary endpoint of change in 6-minute walk distance (6MWD), followed...
Eidos Therapeutics to Host Conference Call and Webcast to Discuss ATTR-CM Phase 3 Trial (ATTRibute-CM) Design
February 25, 2019 08:00 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need...
Eidos Therapeutics to Present at Two Upcoming Investor Conferences
February 21, 2019 08:00 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will present at two upcoming investor conferences. SVB Leerink Global...